Clinical trial · Interventional
A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
NCT01122875CI-TRIAL-00024681completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multicenter, open-label, dose-escalation study of MFGR1877S in patients with relapsed or refractory t(4;14)-positive multiple myeloma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MFGR1877S | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- A
- interventionNames
- Drug: MFGR1877S
Primary outcomes (1)
- measure
- Incidence and nature of dose-limiting toxicities (DLTs)
- timeFrame
- Throughout study or until early study discontinuation
Secondary outcomes (3)
- measure
- Incidence, nature, and severity of adverse events
- timeFrame
- Throughout study or until early study discontinuation
- measure
- Clinical activity of MFGR1877S (objective response, duration of response, and progression-free survival)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * ECOG performance status of 0, 1, or 2 * Life expectancy of at least 12 weeks * Histologic documentation of previously treated t(4;14)-positive multiple myeloma for which no effective standard therapy exists Exclusion Criteria: * Prior use of any monoclonal antibody before study treatment * Treatment with radiotherapy, thalidomide, lenalidomide, bortezomib, any chemotherapeutic agent, or treatment with any other investigational anti-cancer agent within 4 weeks of study treatment * Completion of autologous stem cell transplant within 6 months prior to study treatment * Prior allogeneic stem cell transplant * History of severe allergic or anaphylactic reactions to monoclonal antibody therapy * Evidence of significant, uncontrolled concomitant diseases, including significant cardiovascular disease or pulmonary disease * Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at screening or any recent major episode of infection requiring treatment with IV antibiotics or hospitalization prior to study treatment * Recent major surgery (prior to study treatment), other than for diagnosis * Presence of positive test results for Hepatitis B or Hepatitis C * Known history of HIV seropositive status * Women who are pregnant or lactating * Childbearing potential without agreement to use effective form of contraception for the duration of the study
References
Publications (0)
Data not yet available
No reference posted for this study.